Skip to content

G&A at other companies

ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$8.49M+54.9%
Immunome logo
ImmunomeIMNM
$12.95M+21.1%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$29M+3.6%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$37.59M-8.4%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$62.59M+302%
Erasca, Inc. logo
Erasca, Inc.ERAS
$10.65M+10.2%

Segments

By segment

See full
Reportable Segment$12.74M+70.9%

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.64B+81.4%
Enterprise value$1.32B+288%

Returns & leverage

See full
Return on equity-32.3%
Debt / equity0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's G&A?
Bicara Therapeutics (BCAX) reported G&A of $12.74M in Q1 2026.
How has Bicara Therapeutics's G&A changed year-over-year?
Bicara Therapeutics's G&A increased by 70.9% year-over-year, from $7.46M to $12.74M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.